

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## POSITIVE PROFIT ALERT

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025 (the “**Reporting Period**”) and assessment of the latest information currently available, it is expected that the Group will record a profit of not less than RMB20.0 million for the Reporting Period, compared to a loss of approximately RMB44.9 million for the corresponding period in 2024.

The turnaround from loss to profit of the Company during the Reporting Period was mainly attributable to milestone revenue from three licensed collaborations and sales revenue from the commercialized product. For specific details of these collaborations, please refer to the announcements of the Company dated January 25, 2024, June 5, 2024, and September 29, 2024, respectively.

The information contained in this announcement is only based on the Company’s preliminary assessment of unaudited consolidated management accounts and relevant revenue estimates made available to the Company as at the date of this announcement, which have not been audited or reviewed by the Company’s auditors nor reviewed by the audit committee of the Board. The Company is still in the progress of finalizing the interim results of the Group for the Reporting Period and such interim results may be subject to further adjustment(s) and may be different from the information contained in this announcement. Such information shall not be regarded as a measure or indication of the Group’s current or future operating or financial performance, nor shall it be taken as a representation of the corresponding figures to be provided by the Group in due course in the Company’s interim results announcement for the Reporting Period, which is expected to be published before the end of August 2025 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders’ and investors’ reference only. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the Reporting Period.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, August 13, 2025

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Ms. WONG Yan Ki Angel, Dr. GAO Xiang and Mr. WU Dong as independent non-executive Directors.*